CHRS – coherus oncology, inc. (US:NASDAQ)

News

Coherus Oncology (CHRS) had its "sell (d+)" rating reaffirmed by Weiss Ratings.
Coherus BioSciences Non-GAAP EPS of -$0.34 misses by $0.03, revenue of $12.7M misses by $1.39M [Seeking Alpha]
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
Coherus Oncology to Participate in Upcoming Investor Conferences
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com